PЕТИНОПАТІЯ ПЕРЕДЧАСНО НАРОДЖЕНИХ. ПАТОГЕНЕЗ. МЕХАНІЗМИ РОЗВИТКУ. ЧАСТИНА 1. ФАКТОРИ РИЗИКУ.

Автор(и)

  • Ya. I. Penishkevich Вищий державний навчальний заклад України "Буковинський державний медичний університет", Україна
  • Y. D. Hodovanets Вищий державний навчальний заклад України "Буковинський державний медичний університет", Україна
  • I. V. Koshurba КМУ Міський клінічний пологовий будинок №1 м.Чернівці, Україна

DOI:

https://doi.org/10.24061/2413-4260.VII.3.25.2017.12

Ключові слова:

око, ретинопатія передчасно народжених, патогенез, фактори ризику

Анотація

Резюме. Незрілі сітківки передчасно народжених особливо сприйнятливі до пошкоджень, які переривають нейро-судинне розвиток, приводячи до ретинопатії недоношених. Придушення чинників зростання через гіпероксії і втрата материнської-ембріонального взаємодії призводять до затримки васкуляризації сітківки (фаза 1). Згодом, все більш метаболічно активна, але ще погано васкуляризованная сітківка стає гіпоксичної, стимулюючи викликану фактором зростання вазопрліферацію (фаза 2), яка може попрівесті до відшарування сітківки. У дуже передчасно народжених немовлят, контрольована подача кисню, зменшує, але не усуває ретинопатію недоношених дітей. Ідентифікація та контроль факторів, що сприяють розвитку ретинопатії недоношених, є основоположними для запобігання прогресування в важке, загрозливе зору захворювання і обмеження супутньої патології, з якою захворювання розділяє модифіковані фактори ризику. Стратегії в запобігання ретинопатії недоношених будуть залежати від оптимізації кисневої насиченості, харчування, і нормалізації концентрації основних чинників, таких як інсуліноподібний фактор росту 1 і ω-3 поліненасичені жирні кислоти, так само як обмеження ефектів інфекції і запалення, щоб викликати нормальний ріст і обмежити придушення нервово-судинного розвитку.

Посилання

Silverman WA. Retrolental fibroplasia: a modern parable. New York: Grune & Stratton; 1980.

Campbell K. Intensive oxygen therapy as a possible cause of retrolental fi broplasias: a clinical approach. Med J Aust. 1951 Jul 14;2(2):48-50.

Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1959-69. doi: 10.1056/NEJMoa0911781.

Stenson B, Brocklehurst P, Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med. 2011 Apr 28;364(17):1680-2. doi: 10.1056/NEJMc1101319.

Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-40. doi: 10.1007/s10456-007-9066-0.

Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009 Mar-Apr;24(2):77-81. doi: 10.1080/08820530902800314.

Rivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011;100(4):343-53. doi: 10.1159/000330174.

Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology. 2011;100(2):116-29. doi: 10.1159/000322848.

Mataftsi A, Dimitrakos SA, Adams GG. Mediators involved in retinopathy of prematurity and emerging therapeutic targets. Early Hum Dev. 2011 Oct;87(10):683-90. doi: 10.1016/j.earlhumdev.2011.05.009.

Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med. 2012 Feb;17(1):26-9. doi: 10.1016/j.siny.2011.08.007.

Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012 Dec 27;367(26):2515-26. doi: 10.1056/NEJMra1208129.

Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4.

Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C. Global report on preterm birth and stillbirth (1 of 7): defi nitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010 Feb 23;10(Suppl 1):1. doi: 10.1186/1471-2393-10-S1-S1.

Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012 May 11;379(9832):2151–61. doi: http://dx.doi.org/10.1016/S0140-6736(12)60560-1.

Austeng D, Källen KB, Ewald UW, Jakobsson PG, Holmström GE. Incidence of retinopathy of prematurity in infants born before 27 weeks gestation in Sweden. Arch Ophthalmol. 2009 Oct;127(10):1315-9. doi: 10.1001/archophthalmol.2009.244.

Markestad T, Kaaresen PI, Rønnestad A, Reigstad H, Lossius K, Medbø S, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics. 2005 May;115(5):1289-98.

Allegaert K, de Coen K, Devlieger H. Threshold retinopathy at threshold of viability: the EpiBel study. Br J Ophthalmol. 2004 Feb;88(2):239-42.

Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005 Apr;115(4):990-6.

Weber C, Weninger M, Klebermass K, Reiter G, Wiesinger-Eidenberger G, Brandauer M, et al. Mortality and morbidity in extremely preterm infants (22 to 26 weeks of gestation): Austria 1999–2001. Wien Klin Wochenschr. 2005 Nov;117(21-22):740-6.

Tommiska V, Heinonen K, Lehtonen L, Renlund M, Saarela T, Tammela O, et al. No improvement in outcome of nationwide extremely low birth weight infant populations between 1996–1997 and 1999–2000. Pediatrics. 2007 Jan;119(1):29-36.

Fledelius HC, Dahl H. Retinopathy of prematurity, a decrease in frequency and severity. Trends over 16 years in a Danish county. Acta Ophthalmol Scand. 2000 Jun;78(3):359-61.

Lundqvist P, Källen K, Hallström I, Westas LH. Trends in outcomes for very preterm infants in the southern region of Sweden over a 10-year period. Acta Paediatr. 2009 Apr;98(4):648-53. doi: 10.1111/j.1651-2227.2008.01155.x.

Haines L, Fielder AR, Scrivener R, Wilkinson AR. Retinopathy of prematurity in the UK I: the organisation of services for screening and treatment. Eye (Lond). 2002 Jan;16(1):33-8.

Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):240-4.

Holmström GE, Hellström A, Jakobsson PG, Lundgren P, Tornqvist K, Wallin A. Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol. 2012 Nov;130(11):1418-24. doi: 10.1001/archophthalmol.2012.2357.

Tan SZ, Dhaliwal C, Becher JC, Fleck B. Trends in the incidence of retinopathy of prematurity in Lothian, south-east Scotland, from 1990 to 2009. Arch Dis Child Fetal Neonatal Ed. 2012 Jul;97(4):310-1. doi: 10.1136/fetalneonatal-2011-301464.

Hameed B, Shyamanur K, Kotecha S, Manktelow BN, Woodruff G, Draper ES, et al. Trends in the incidence of severe retinopathy of prematurity in a geographically defined population over a 10-year period. Pediatrics. 2004 Jun;113(6):1653-7.

Lad EM, Nguyen TC, Morton JM, Moshfeghi DM. Retinopathy of prematurity in the United States. Br J Ophthalmol. 2008 Mar;92(3):320-5. doi: 10.1136/bjo.2007.126201.

Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol. 2009 Sep;148(3):451-8. doi: 10.1016/j.ajo.2009.04.018.

Gunn DJ, Cartwright DW, Gole GA. Incidence of retinopathy of prematurity in extremely premature infants over an 18-year period. Clin Experiment Ophthalmol. 2012 Jan-Feb;40(1):93-9. doi: 10.1111/j.1442-9071.2011.02724.x.

Zin AA, Moreira ME, Bunce C, Darlow BA, Gilbert CE. Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications. Pediatrics. 2010 ; 126: e410–17.

Darlow BA, Zin AA, Beecroft G, Moreira ME, Gilbert CE. Capacity building of nurses providing neonatal care in Rio de Janeiro, Brazil: methods for the POINTS of care project to enhance nursing education and reduce adverse neonatal outcomes. BMC Nurs. 2012 Mar 12;11:3. doi: 10.1186/1472-6955-11-3.

Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82. doi: 10.1167/iovs.08-2584.

Patz A, Hoeck LE, De la Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia: I. Nursery observations. Am J Ophthalmol. 1952 Sept;35(9):1248–53.

Ashton N. Pathological basis of retrolental fibroplasia. Br J Ophthalmol. 1954 Jul;38(7):385–96.

Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11.

Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565-73. doi: 10.1038/nprot.2009.187.

Nicolaides KH, Economides DL, Soothill PW. Blood gases, pH, and lactate in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol. 1989 Oct;161(4):996-1001.

Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008 Feb;118(2):526-33. doi: 10.1172/JCI33813.

Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1329-35. doi: 10.1167/iovs.08-2521.

Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995 Jan 31;92(3):905-9.

Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996 Oct;114(10):1219-28.

Shah PK, Narendran V, Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed. 2012 Sep;97(5):F371-5. doi: 10.1136/fetalneonatal-2011-301121.

Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993 Mar;34(3):576-85.

Hellström A, Engström E, Hård AL, Albertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor I defi ciency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003 Nov;112(5):1016-20.

Connor KM, Sangiovanni JP, Löfqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007 Jul;13(7):868-873. doi: 10.1038/nm1591.

Pawlik D, Lauterbach R, Turyk E. Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics. 2011 Feb;127(2):223-8. doi: 10.1542/peds.2010-2427.

Aiello L.P., Pierce E.A., Foley E.D., Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995 Nov 7;92(23):10457-61.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005 Aug 25;353(8):782-92.

Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res. 2009 Nov;28(6):452–82. doi: 10.1016/j.preteyeres.2009.06.003.

Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991 Nov;98(11):1628-40.

Austeng D, Källen KB, Hellström A, Jakobsson PG, Johansson K, Tornqvist K, et al. Screening for retinopathy of prematurity in infants born before 27 weeks’ gestation in Sweden. Arch Ophthalmol. 2011 Feb;129(2):167-72. doi: 10.1001/archophthalmol.2010.346.

Chen ML, Allred EN, Hecht JL, Onderdonk A, VanderVeen D, Wallace DK, et al. Placenta microbiology and histology and the risk for severe retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2011 Sep 1;52(10):7052-8. doi: 10.1167/iovs.11-7380.

Bolton DP, Cross KW. Further observations on cost of preventing retrolental fibroplasia. Lancet. 1974 Mar 16;1(7855):445-8.

Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):106–10. doi: 10.1136/fn.84.2.F106.

Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol. 2004 Mar;24(3):164-8.

Sun SC. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res. 2002;51:350A.

Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W. NeOProM: neonatal oxygenation prospective meta-analysis collaboration study protocol. BMC Pediatr. 2011 Jan;11(1):6. doi: 10.1186/1471-2431-11-6.

Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000 Feb;105(2):295-310.

Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003 Sep 4;349(10):959-67. doi: 10.1056/NEJMoa023080.

Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010 Jun;125(6):1483-92. doi: 10.1542/peds.2009-2218.

Saito Y, Omoto T, Cho Y, Hatsukawa Y, Fujimura M, Takeuchi T. The progression of retinopathy of prematurity and fl uctuation in blood gas tension. Graefes Arch Clin Exp Ophthalmol. 1993 Mar;231(3):151–6. doi: 10.1007/BF00920938.

Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet. 1995 Dec 2;346(8988):1464-5.

York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol. 2004 Feb;24(2):82-7. doi: 10.1038/sj.jp.7211040.

Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994 Dec;36(6):724-31. doi: 10.1203/00006450-199412000-00007.

Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995 Sep;36(10):2063-70.

Di Fiore JM, Bloom JN, Orge F, Schutt A, Schluchter M, Cheruvu VK, et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr. 2010 Jul;157(1):69-73. doi: 10.1016/j.jpeds.2010.01.046.

Coleman RJ, Beharry KD, Brock RS, Abad-Santos P, Abad-Santos M, Modanlou HD. Effects of brief, clustered versus dispersed hypoxic episodes on systemic and ocular growth factors in a rat model of oxygen-induced retinopathy. Pediatr Res. 2008 Jul;64(1):50-5. doi: 10.1203/PDR.0b013e31817307ac.

Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003 Feb;111(2):339-45.

Castillo A, Deulofeut R, Critz A, Sola A. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology. Acta Paediatr. 2011 Feb; 100(2): 188–92. doi: 10.1111/j.1651-2227.2010.02001.x.

Hellstrom A, Smith LEH, Dammann O. Retinopathy of prematurity. Lancet. 2013 Oct 26;382(9902):1445–57. doi: 10.1016/S0140-6736(13)60178-6.

Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology. 2011;100(2):116-29. doi: 10.1159/000322848.

##submission.downloads##

Опубліковано

2017-11-09

Як цитувати

Penishkevich, Y. I., Hodovanets, Y. D., & Koshurba, I. V. (2017). PЕТИНОПАТІЯ ПЕРЕДЧАСНО НАРОДЖЕНИХ. ПАТОГЕНЕЗ. МЕХАНІЗМИ РОЗВИТКУ. ЧАСТИНА 1. ФАКТОРИ РИЗИКУ. Неонатологія, хірургія та перинатальна медицина, 7(3(25), 75–81. https://doi.org/10.24061/2413-4260.VII.3.25.2017.12